Floatz logo

Ipragliflozin

Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)

Yonsei UniversitySmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD) cohort.

Asset / SponsorPhaseRating
Metformin
Yonsei University
Phase 4BB
Pioglitazone
Yonsei University
Phase 4BB

Same molecule, other indications

Ipragliflozin is also rated in:

type 2 diabetes mellitusDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →